VANCOUVER, BC , Nov. 14, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its third quarter financial results and operational highlights for the period ended September 30, 2024 . "This quarter we continued to grow our position as the premier global supplier of cGMP botanical psilocybin," said... Read More

VANCOUVER, BC , Oct. 4, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announces that, it has issued 5,600,000 common shares in the capital of the Company (the " Common Shares ") at a price of $0.05 per Common Share to Filament Health SPV – Allocations Funds LLC, Bioconnect Ventures –... Read More

VANCOUVER, BC , Aug. 14, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended June 30, 2024 . "This quarter we were proud to announce a significant milestone - Health Canada and US FDA authorization of a Phase II... Read More

Developments include acceptance of 12 Australian patents, issuance of 5 Canadian patents and 3 patents in the United States Filament's industry-leading global IP portfolio contains 46 allowed patents relating to the extraction, purification, standardization, and delivery of naturally-derived psychedelic APIs VANCOUVER, BC , Aug. 13, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " or... Read More

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the " Acquiror "), a shareholder of Filament Health Corp. (" Filament "), announces that on June 12, 2024, it was issued 42,284,443 common shares of Filament (the " Common Shares ") from the conversion of a convertible note due July 13, 2024 (" Note ") and the exercise of the Acquiror's outstanding warrants (" Warrants ") to... Read More

VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announces that, further to its press release dated June 3, 2024 , it has completed its previously announced C$1.0 million bridge financing (the " Financing "). Pursuant to the Financing, Negev Capital Fund One, LP (" Negev... Read More

Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada VANCOUVER, BC , June 3, 2024 /CNW/ - Filament Health Corp . (OTCQB: FLHLF) (Cboe CA: FH) (FSE:7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announced Health Canada and the United States Food and Drug Administration (" FDA ")... Read More

VANCOUVER, BC , June 3, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announced that it has entered into agreements with Negev Capital Fund One, LP (" Negev "), a leading psychedelic drug development venture fund and existing investor in the Company, and Benjamin Lightburn , the Chief Executive... Read More

VANCOUVER, BC , May 14, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended March 31, 2024 . "This quarter we have continued to advance Filament's drug development efforts in substance use disorders, as evidenced by... Read More

VANCOUVER, BC , May 3, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical-stage natural psychedelic drug development company, today announced that Chris Wagner has stepped down from his position as Director on the Company's board of directors due to the requirements of a new role, effective April 30, 2024 . Wagner commented: "I have been part of Filament's... Read More

VANCOUVER, BC , April 3, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, will be participating in the Water Tower Research Fireside Chat Series on April 4, 2024 , at 12:00 pm ET . This event is open access for all investors. Topics will include: An update on Filament's drug development programs and partnership... Read More

VANCOUVER, BC , April 2, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights for the period ended December 31, 2023 . "During the fourth quarter, we continued to lay the foundation for the advancement of our lead program, PEX010, into... Read More

VANCOUVER, BC , March 28, 2024 /CNW/ - Filament Health Corp . (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced the appointment of Michael Messinger, CPA, to its Board of Directors (the " Board "). Mr. Messinger will also serve as the Chair of the Company's Audit Committee. "I am pleased to welcome Mr. Messinger to our Board... Read More

Research institutions in the United States , Canada , Israel , and Belgium , including Johns Hopkins University , will study PEX010, Filament's botanical psilocybin drug candidate VANCOUVER, BC , March 19, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, announced that since March 1, 2024 it has shipped its... Read More

Hadassah University Hospital will study PEX010, Filament's botanical psilocybin drug candidate, for the treatment of post-traumatic stress disorder and obsessive-compulsive disorder VANCOUVER, BC , Feb. 15, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE:7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has successfully completed an... Read More

The active IND allows initiation of US research with Filament's botanical psilocybin drug candidate for the potential treatment of substance use disorders including OUD VANCOUVER, BC , Jan. 31, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announced that the U.S. Food and Drug Administration... Read More

Reset Mind Sciences Ltd. has received a shipment of PEX010, Filament's botanical psilocybin drug candidate VANCOUVER, BC , Jan. 17, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it successfully completed an export of PEX010, the Company's botanical psilocybin drug candidate, to Perth... Read More

VANCOUVER, BC , Jan. 2, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Maureen O'Connell has stepped down from her position as Director and Audit Committee Chair on the Company's board of directors, effective December 31, 2023 . O'Connell commented: "I have been part of Filament's... Read More

VANCOUVER, BC , Dec. 19, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announced that the Business Combination Agreement, by and among the Company, Jupiter Acquisition Corporation (NASDAQ: JAQC) (" Jupiter "), 1427702 B .C. Ltd. (" TopCo ") and Filament Merger Sub LLC, dated as of July 18, 2023 (as... Read More

VANCOUVER, BC , Dec. 18, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announced that the special meeting of its securityholders held this Monday, December 18, 2023 at 9:30 a.m. ( Vancouver time) (the " Special Meeting ") to approve, among other things, the Company's proposed arrangement (the "... Read More

VANCOUVER, BC , Dec. 11, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, announces that the special meeting of its securityholders to be held this Monday, December 11, 2023 at 9:30 a.m. ( Vancouver time) (the " Special Meeting ") to approve, among other things, the Company's proposed arrangement (the "... Read More

VANCOUVER, BC , Dec. 7, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, announces that, further to its press release dated December 6, 2023 (the " Previous Press Release "), the Company has filed amended pro forma financial statements (the " Amended Pro Forma Financials "). The Amended Pro Forma Financials... Read More

VANCOUVER, BC , Dec. 6, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, is pleased to announce that, further to its press release dated November 23, 2023, the Company has entered into a definitive securities purchase agreement (the " Securities Purchase Agreement ") with Helena Global Investment... Read More

Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to announce the signing of a non-binding term sheet for potential funding of up to US$14.4 million. The funding is in collaboration with an affiliate of Helena Partners Inc., a Cayman-Islands-based advisor and investor. The infusion of capital is expected to significantly bolster Filament Health's operations, particularly in advancing its drug development... Read More

Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to share the news that the company has received approval from Health Canada for a phase 2 clinical trial, which will be conducted at the University of British Columbia. This groundbreaking trial will focus on investigating the effects of PEX010, a botanical psilocybin drug candidate developed by Filament, specifically in the context of treating opioid use... Read More

VANCOUVER, BC , Nov. 23, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical–stage natural psychedelic drug development company, today announced that the Company has signed a non-binding term sheet (the "Term Sheet") providing for up to US$14.4 million in funding through a convertible note (the "Financing") with an affiliate of Helena Partners Inc., a... Read More

VANCOUVER, British Columbia, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA)(OTCQB:PMBHF), a Canadian biotechnology company dedicated to the research and development of clinical-grade LaNeo™ MDMA and novel MDXX compounds, and Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, today announced the GMP... Read More

VANCOUVER, BC , Nov. 14, 2023 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its third quarter financial results and operational highlights for the period ended September 30, 2023 . "This quarter we have made significant strides towards our proposed Business Combination with Jupiter Acquisition Corporation,... Read More

VANCOUVER, BC , Nov. 14, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition Corporation (NASDAQ:JAQC) ("Jupiter"), a special purpose acquisition company ("SPAC"), today announced that the U.S. Securities and Exchange Commission (the "SEC") has declared effective the registration statement... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2023) - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, is pleased to announce that shareholders overwhelmingly approved all proposed resolutions at its Annual General Meeting (" AGM ") of shareholders held virtually this morning. At the AGM, there were 18... Read More

Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to share the exciting news that Filament Health has received approval from Health Canada for a phase 2 clinical trial, which will be conducted at the University of British Columbia. This groundbreaking trial will focus on investigating the effects of PEX010, a botanical psilocybin drug candidate developed by Filament, specifically in the context of... Read More

Filament-sponsored research will study its botanical psilocybin drug candidate, PEX010 VANCOUVER, BC , Oct. 10, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE:7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announced Health Canada approval for a phase 2 clinical trial at the University of British Columbia (UBC). The trial will study the effects of... Read More

VANCOUVER, BC , Sept. 29, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE:7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announced that it intends to complete, subject to regulatory approval, a non-brokered private placement for gross proceeds of up to C$2,000,000 (the " Offering "). Negev Capital, a leading venture fund in the psychedelic drug... Read More

The import to Filament's Metro Vancouver facility was conducted in collaboration with the Peruvian government and facilitated by Filament Health and Jaguar Health VANCOUVER, BC , Sept. 21, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or "Filament Health"), a clinical-stage natural psychedelic drug development company, today announced that Magdalena Biosciences ("Magdalena"), a joint... Read More

Reset Pharma has licensed Filament's botanical psilocybin drug candidate for a phase 2 clinical trial studying demoralization syndrome VANCOUVER, BC , Aug. 31, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or "Filament Health"), a clinical-stage natural psychedelic drug development company, today announced that it has entered into a licensing agreement with Reset Pharmaceuticals Inc.... Read More

VANCOUVER, BC , Aug. 15, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition Corporation ( NASDAQ:JAQC ) ("Jupiter"), a special purpose acquisition company ("SPAC"), today announced the filing of a registration statement by 1427702 B .C. Ltd. ("TopCo") on Form F-4 (the "Registration... Read More

VANCOUVER, BC , Aug. 15, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended June 30, 2023 . "I'm proud to report on another highly productive quarter," said Benjamin Lightburn , CEO and Co-Founder of Filament Health. "The... Read More

The University of Washington and the University of California, Los Angeles have been approved to study PEX010 in clinical trials for mental health conditions VANCOUVER, BC , Aug. 8, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announced approval from the United States Food and Drug Administration... Read More

Financing led by psychedelic investment fund Negev Capital VANCOUVER, BC , July 24, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, is pleased to announce an increase in the size of its previously announced private placement offering and that, further to its news release dated July 19, 2023 , the Company has... Read More

Financing led by premier psychedelics focused investment fund Negev Capital VANCOUVER, BC , July 19, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announced that it intends to complete, subject to regulatory approval, a non-brokered private placement for gross proceeds of up to C$2,000,000 (the "... Read More

Business combination ascribes Filament US$176 million in equity value representing US$0.85 per Filament share and reflects a pro forma enterprise valuation of approximately US$210 million ; combined company to be listed on Nasdaq Transaction expected to accelerate the progression of Filament's botanical psychedelic drug development platform and is anticipated to close in fourth quarter 2023 VANCOUVER, BC and HOBE SOUND, Fla.... Read More

VANCOUVER, BC , July 14, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company today announced a change of auditor from Crowe MacKay LLP (the " Former Auditor ") to MNP LLP (the " Successor Auditor "). At the request of the Company, the Former Auditor resigned as the auditor of the Company effective July 14, 2023... Read More

The CIHR is funding clinical trials through its Operating Grants for Psilocybin-assisted Psychotherapy for Mental Health and Substance Use Disorders VANCOUVER, BC , July 6, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical–stage natural psychedelic drug development company, today announced that it will supply psilocybin for two clinical trials which have... Read More

NeoLumina's license for Filament's botanical psilocybin drug candidate provides exclusive global right to clinical and commercial development for eating disorders VANCOUVER, BC , June 30, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced an exclusive global licensing agreement with NeoLumina... Read More

Healthy subjects have been dosed with Filament's botanical psilocybin and psilocin drug candidates VANCOUVER, BC , May 30, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical–stage natural psychedelic drug development company, today announced interim safety reporting from its Phase I clinical trial in partnership with the University of California, San Francisco... Read More

The botanical raw material was shipped to Filament's Vancouver facility for analysis and development into ibogaine extract VANCOUVER, BC , May 17, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced the completion of the first-ever Nagoya Protocol-compliant import of Tabernanthe iboga root from... Read More

VANCOUVER, BC , May 12, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended March 31, 2023 . "We are pleased to report on another highly productive quarter," said Benjamin Lightburn , CEO and Co-Founder of Filament Health.... Read More

Attendees will gain insight into the Company's drug development strategy, growing partnership network, and clinical trials VANCOUVER, BC , May 8, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it will host a virtual update for investors and shareholders on Thursday, May 18, 2023 at 2:00... Read More

VANCOUVER, BC , April 25, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced upcoming event appearances and media coverage for Spring 2023. EVENTS Filament CEO and Co-Founder Benjamin Lightburn has been invited to speak at MAPS Psychedelic Science Conference in Denver . Mr. Lightburn will... Read More

VANCOUVER, British Columbia, April 11, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA), a Canadian biotechnology company dedicated to the research and development of clinical-grade LaNeo™ MDMA and novel MDXX compounds, and Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, today announced the GMP release of MDMA... Read More

Filament subsidiary Psilo Scientific manufactured the drug product on behalf of PharmAla for distribution to clinical trial customers and authorized patients. VANCOUVER, BC , April 11, 2023 /CNW/ - Filament Health Corp . (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, and PharmAla Biotech Holdings Inc. ("PharmAla")(CSE:MDMA), a Canadian... Read More

VANCOUVER, BC , March 31, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights for the period ended December 31, 2022 . "During the fourth quarter, Filament expanded its revenue-generating partnership network, and announced a worldwide... Read More

The clinical trial will study PEX010, Filament's botanical psilocybin drug candidate VANCOUVER, BC , March 15, 2023 /CNW/ - Filament Health Corp . (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical–stage natural psychedelic drug development company, today announced approval from the United States Food and Drug Administration (FDA) for a clinical trial at the University of California San... Read More

CAMH will study PEX010, Filament's botanical psilocybin drug candidate, in a Health Canada-approved clinical trial for mild cognitive impairment VANCOUVER, BC , Feb. 14, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical–stage natural psychedelic drug development company, today announced a second agreement to supply the Centre for Addiction and Mental Health... Read More

Danish psychiatric research hospital will study the effects of Filament's natural psilocybin drug candidate for treating alcohol use disorder VANCOUVER, BC , Jan. 18, 2023 /CNW/ - Filament Health Corp . (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical–stage natural psychedelic drug development company, today announced the approval of a clinical trial in partnership with Psychiatric Centre... Read More

New venture aligns with Jaguar's mental health Entheogen Therapeutics Initiative (ETI) and Filament's corporate mission to develop novel, natural prescription medicines from plants Magdalena Biosciences will leverage Jaguar's proprietary medicinal plant library and Filament's proprietary drug development technology Magdalena Biosciences is currently valued at US$5.0 million based on initial and tranched funding of US$1.0... Read More

VANCOUVER, BC , Dec. 30, 2022 /CNW/ - F ilament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced the distribution of a year-end letter from Chief Executive Officer, Benjamin Lightburn , which can be viewed on Filament's website . The letter highlights key milestones achieved by the Company including beginning the... Read More

The agreement expands on an existing partnership and grants Psyence the right to commercialize Filament's natural psilocybin drug candidate PEX010 25mg within palliative care VANCOUVER, BC , Dec. 15, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament"), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc (CSE:PSYG) (OTCQB: PSYGF) ("Psyence" and, together with... Read More

CAMH to use Filament's natural psilocybin drug candidate for a clinical trial studying treatment-resistant depression VANCOUVER, BC , Nov. 17, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announced an agreement with the Centre for Addiction and Mental Health (CAMH), Canada's largest mental health... Read More

VANCOUVER, BC , Nov. 10, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended September 30, 2022 . "Our third quarter demonstrated Filament's continued progress both internally and externally," said Filament CEO Benjamin... Read More

Attendees will gain insight into the Company's clinical trials, partnership network, and growth plans Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it will host a virtual update for investors and shareholders on Wednesday, October 19, 2022 at 2:00 p.m. Eastern ( 11:00 a.m. Pacific). During the event,... Read More

Subjects were given Filament's psilocybin drug candidate in the first Canadian trial with the purpose of psychedelic therapist training Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, and ATMA Journey Centers ("ATMA") , a company focused on delivering effective and innovative experiences that leverage the potential of... Read More

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announced the appointment of Dr. Konstantin Adamsky of Negev Capital to its Board of Directors, and Jeff Chilton of Nammex to the Company's Advisory Council. Konstantin Adamsky , PhD, is the Chief Operating Officer of Negev Capital, a psychedelic medical... Read More

The patent describes the extraction and standardization of stable doses of psychedelic compounds and strengthens Filament's industry-leading IP portfolio Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued an eighth patent for the extraction and standardization of natural psilocybin and... Read More

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended June 30, 2022 . "We are pleased to report on another highly productive quarter," said Filament CEO Benjamin Lightburn . "Filament continues to demonstrate its position as a leader in... Read More

The newly-launched program, led by Canadian non-profit TheraPsil, is the world's largest medical psilocybin access and data project Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, today announced its participation in Project Solace, the world's largest medical psilocybin access and data project. Project Solace is led... Read More

Financing led by psychedelic investment fund Negev Capital and leading functional mushroom manufacturer Nammex Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, is pleased to announce that, further to its news release dated June 30, 2022 , the Company has completed its previously announced non-brokered private placement for... Read More

The patent describes the extraction and standardization of stable doses of psychedelic compounds Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a third patent by the United States Patent and Trademark Office (USPTO) for the extraction and standardization of natural psilocybin and... Read More

The trial, conducted at UCSF's TrPR Lab, is first to use naturally derived psychedelic drug candidates and first to directly administer psilocin, the active form of psilocybin Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament"), a clinical-stage natural psychedelic drug development company, today announced the beginning of dosing in the first United States Food and Drug Administration (FDA)-approved clinical... Read More

The patent describes the extraction and standardization of stable doses of psychedelic compounds Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a sixth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament's latest patent... Read More

Financing driven by psychedelic investment fund Negev Capital and leading functional mushroom manufacturer Nammex Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, is pleased to announce that it intends to complete, subject to regulatory approval, a non-brokered private placement for gross proceeds of up to C$2,500,000 (the... Read More

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psychedelic drug development company, is pleased to announce that shareholders overwhelmingly approved all proposed resolutions at its Annual General Meeting (" AGM ") of shareholders held virtually this morning. At the AGM, there were 28 holders of the common shares of Filament (the " Common Shares ")... Read More

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that a patient has been dosed with one of Filament's drug candidates through the Health Canada Special Access Program (SAP). Filament is continuing the development of its drug candidates through clinical trials in order to establish their safety and efficacy.... Read More

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has cultivated its 70th variety of psilocybin-containing mushrooms at its 3,500 square foot GMP-compliant facility in Metro Vancouver. Filament also announced the successful development of standardized, pharmaceutical-grade ayahuasca extract, designed... Read More

Drug discovery collaboration will leverage the botanical drug development expertise of both companies Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) and Jaguar Health, Inc. (NASDAQ: JAGX) today announced that the companies have signed a letter of intent to enter a collaboration agreement to develop botanical prescription drugs for specific psychoactive target indications in the United States . The goal of the... Read More

The patent describes the extraction and standardization of stable doses of psychedelic compounds The Company also reports first quarter 2022 financial results and operational highlights Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a second patent by the United States Patent and... Read More

The patent describes the extraction and standardization of stable doses of psychedelic compounds Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a fourth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament's latest patent... Read More

The partnership leverages Psyence's expertise in fungi cultivation and palliative care as well as Filament's expertise in the manufacture of pharmaceutical grade drug candidates Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development... Read More

The patent describes the extraction and standardization of stable doses of psychedelic compounds Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a patent by the United States Patent... Read More

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced it has held a pre-investigational new drug application (PIND) meeting with the United States Food and Drug Administration (FDA) Division of Psychiatry (The... Read More

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, announces that the Company will participate in the following upcoming investor conferences in April 2022 : Benzinga Psychedelics Capital Conference to be held in person at the... Read More

Filament announced FDA approval for the first clinical trial using naturally-sourced psychedelic substances in November 2021 The Company signed multiple revenue-generating licensing agreements allowing partners to use its natural psilocybin drug candidate for clinical trials Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE:... Read More

The patent describes the extraction and standardization of stable doses of psychedelic compounds Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a second patent by the Canadian... Read More

Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Benjamin Lightburn , Chief Executive Officer, will participate in the 34th Annual Roth Conference on March 13-15, 2022 . The conference will be held at The... Read More

ATMA will use Filament's proprietary botanical drug candidate for clinical trials Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has entered into a licensing agreement with ATMA Journey Centers... Read More

Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that its auditors have completed a review engagement of Filament's Q3 FS (defined herein). The Amended Statements (defined herein) do not include any amendment to... Read More

Filament is one of a small number of Canadian companies to have Good Manufacturing Practices-compliant psilocybin drug candidates entering Health Canada-approved clinical trials Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development... Read More

Filament will license PEX010, its proprietary botanical psilocybin drug candidate, to Cybin Therapeutics for use in two upcoming Phase II clinical trials awaiting Health Canada approval Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development... Read More

Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), commends the formal restoration of access to restricted drugs through the Health Canada Special Access Program (SAP). The SAP allows health care practitioners to request for patients, on an emergency basis, access to drugs that are not yet... Read More

The clinical trial at the University of Toronto will study low doses of psilocybin in healthy subjects with persistent depressive disorder Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Health Canada... Read More

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it will participate in the following upcoming events in December 2021 : Horizons: Perspectives on Psychedelics Conference to be held virtually and live in... Read More

FDA Authorization of Historic Phase I Clinical Trial Using All-Natural Psychedelic Compounds and Direct Psilocin Administration for the First Time Granted First and Only Patent for Extraction and Standardization of Natural Psilocybin Health Canada Dealer's License Enables Production and Distribution of All Natural cGMP-Grade... Read More

The Phase 1 Trial is Taking Place at the Translational Psychedelic Research Program at the University of California San Francisco Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), an exclusively-natural psychedelic drug discovery company, announces FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic substances. In addition, this approval is the... Read More